Phaseline

Companies › Jemincare

Jemincare: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 4 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Immunology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JYB1904–Phase 3Chronic Spontaneous UrticariaJun 2027
JMKX003142–Phase 2ADPKD (Autosomal Dominant Polycystic Kidney Disease)Feb 2027
JMKX000197 Injection–Phase 1Malignant Pleural Effusions (Mpe)Nov 2026
JMKX003948–Phase 1Renal Cell Carcinoma MetastaticApr 2027
JMKX001899
KRAS G12C inhibitor
–Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)Dec 2027
JMKX005425–Phase 1Advanced Solid TumorsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06509334JYB1904Phase 2Chronic Spontaneous UrticariaImmunologyJul 2026
NCT06740019JMKX000197 InjectionPhase 1Malignant Pleural Effusions (Mpe)OncologyNov 2026
NCT06800651JMKX003142Phase 2ADPKD (Autosomal Dominant Polycystic Kidney Disease)GenitourinaryFeb 2027
NCT06321250JMKX003948Phase 1Renal Cell Carcinoma MetastaticOncologyApr 2027
NCT07402213JYB1904Phase 3Chronic Spontaneous UrticariaImmunologyJun 2027
NCT06946927JMKX001899Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)OncologyDec 2027
NCT07208136JMKX005425Phase 1Advanced Solid TumorsOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Jacobio Pharmaceuticals DualityBio Bio-Thera Solutions InSilico Medicine Hong Kong Nanjing Sanhome Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.